檢索結果 - C. David Jenkins
- Showing 1 - 3 results of 3
-
1
-
2
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM tria... 由 Nadine Tung, Banu K. Arun, Michele R. Hacker, Erin Hofstatter, Deborah Toppmeyer, Steven J. Isakoff, Virginia F. Borges, Robert D. Legare, Claudine Isaacs, Antonio C. Wolff, P. Kelly Marcom, Erica L. Mayer, Paulina Lange, Andrew J. Goss, C. David Jenkins, Ian E. Krop, Eric P. Winer, Stuart J. Schnitt, Judy E. Garber
出版 2020Artigo -
3
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes 由 Nadine Tung, Mark E. Robson, Steffen Ventz, Cesar A. Santa‐Maria, Rita Nanda, P. Kelly Marcom, Payal D. Shah, Tarah J. Ballinger, Eddy S. Yang, Shaveta Vinayak, Michelle Melisko, Adam Brufsky, Michelle K. DeMeo, C. David Jenkins, Susan M. Domchek, Alan D. D’Andrea, Nancy U. Lin, Melissa E. Hughes, Lisa A. Carey, Nick Wagle, Gerburg M. Wulf, Ian E. Krop, Antonio C. Wolff, Eric P. Winer, Judy E. Garber
出版 2020Artigo
相關主題
Internal medicine
Medicine
Breast cancer
Cancer
Chemotherapy
Oncology
BRCA mutation
Biology
Blood pressure
CHEK2
Cancer research
Cardiology
Cholesterol
Cohort
Coronary heart disease
Cyclophosphamide
Diastole
Disease
Doxorubicin
Environmental health
Framingham Risk Score
Gene
Genetics
Germline mutation
Metastatic breast cancer
Mutation
Myocardial infarction
Olaparib
PALB2
PARP inhibitor